1.He J, Chai X, Zhang Q, Wang Y, Wang Y, Yang X, Wu J, Feng B, Sun J, Rui W, Ze S, Fu Y, Zhao Y, Zhang Y, Zhang Y, Liu M, Liu C, She M, Hu X, Ma X, Yang H, Li D, Zhao S, Li G, Zhang Z, Tian Z, Ma Y, Cao L, Yi B, Li D, Nussinov R, Eng C, Chan TA, Ruppin E, Gutkind JS, Cheng F, Liu M, Lu W. The lactate receptor HCAR1 drives the recruitment of immunosuppressive PMN-MDSCs in colorectal cancer. Nat Immunol. 2025 Mar;26(3):391-403.

2.Wang X, Wu X, Tan B, Zhu L, Zhang Y, Lin L, Xiao Y, Sun A, Wan X, Liu S, Liu Y, Ta N, Zhang H, Song J, Li T, Zhou L, Yin J, Ye L, Lu H, Hong J, Cheng H, Wang P, Li W, Chen J, Zhang J, Luo J, Huang M, Guo L, Pan X, Jin Y, Ye W, Dai L, Zhu J, Sun L, Zheng B, Li D, He Y, Liu M, Wu H, Du B, Xu H. Allogeneic CD19-targeted CAR-T therapy in patients with severe myositis and systemic sclerosis. Cell. 2024 Sep 5;187(18):4890-4904.e9.

3.Zhang J, Hu Y, Yang J, Li W, Zhang M, Wang Q, Zhang L, Wei G, Tian Y, Zhao K, Chen A, Tan B, Cui J, Li D, Li Y, Qi Y, Wang D, Wu Y, Li D, Du B, Liu M, Huang H. Non-viral, specifically targeted CAR-T cells achieve high safety and efficacy in B-NHL. Nature. 2022 Sep;609(7926):369-374.

4.Fu B, Liao J, Chen S, Li W, Wang Q, Hu J, Yang F, Hsiao S, Jiang Y, Wang L, Chen F, Zhang Y, Wang X, Li D, Liu M, Wu Y. CRISPR-Cas9-mediated gene editing of the BCL11A enhancer for pediatric β0/β0 transfusion-dependent β-thalassemia. Nat Med. 2022 Aug;28(8):1573-1580.

5.Li L, Mi D, Pei H, Duan Q, Wang X, Zhou W, Jin J, Li D, Liu M, Chen Y. In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15. Signal Transduct Target Ther. 2020 Jul 27;5(1):129.

6.Wang L, Li L, Ma Y, Hu H, Li Q, Yang Y, Liu W, Yin S, Li W, Fu B, Kurita R, Nakamura Y, Liu M, Lai Y, Li D. Reactivation of γ-globin expression through Cas9 or base editor to treat β-hemoglobinopathies. Cell Res. 2020 Mar;30(3):276-278.

7.Li L, Mi D, Pei H, Duan Q, Wang X, Zhou W, Jin J, Li D, Liu M, Chen Y. In vivo target protein degradation induced by PROTACs based on E3 ligase DCAF15. Signal Transduct Target Ther. 2020 Jul 27;5(1):129.

8.Luo J, Yang Z, Ma Y, Yue Z, Lin H, Qu G, Huang J, Dai W, Li C, Zheng C, Xu L, Chen H, Wang J, Li D, Siwko S, Penninger JM, Ning G, Xiao J, Liu M. LGR4 is a receptor for RANKL and negatively regulates osteoclast differentiation and bone resorption. Nat Med. 2016 May;22(5):539-46.

9.Zhang T, Li J, He Y, Yang F, Hao Y, Jin W, Wu J, Sun Z, Li Y, Chen Y, Yi Z, Liu M. A small molecule targeting myoferlin exerts promising anti-tumor effects on breast cancer. Nat Commun. 2018 Sep 13;9(1):3726.

10.Wang J, Hu K, Guo J, Cheng F, Lv J, Jiang W, Lu W, Liu J, Pang X, Liu M. Suppression of KRas-mutant cancer through the combined inhibition of KRAS with PLK1 and ROCK. Nat Commun. 2016 May 19;7:11363.